Guidelines for Anticoagulation in Paediatric Cardiac Patients

Size: px
Start display at page:

Download "Guidelines for Anticoagulation in Paediatric Cardiac Patients"

Transcription

1 Leeds Children s Hospital Guidelines for Anticoagulation in Paediatric Cardiac Patients SURGICAL PATIENTS Preoperative Management Blalock-Taussig (BT) Shunt / Fontan circulation / Sano Shunt and Severe cyanosis Receiving Aspirin / Dipyridamole / Clopidogrel Stop aspirin / dipyridamole 2 days prior to surgery (i.e. if the child s operation is on Tuesday, then their last dose of aspirin / dipyridamole will be on Saturday). Admit the day before for intravenous fluids +/- intravenous heparin depending on the haematocrit. It is significant if it is greater than Start heparin (prophylactic) at 10units/Kg/hour. Check APTT at 4 hours, if below 85 continue at same rate. At the unlikely event of APTT greater than 85 stop heparin and recheck APTT in 1hour. Discuss results with paediatric cardiology consultant/registrar. Check APTT daily, 4 hours after syringe changes. MVR / AVR on Warfarin Stop warfarin 2 days prior to surgery (i.e. of the child s operation is on Tuesday, then their last dose of warfarin will be on Saturday). The INR will need to be checked on the day of admission, the day before the operation. If the INR is between , then no further anticoagulation treatment is required prior to the operation. However if the INR is less than 1.5 then a stat dose of therapeutic tinzaparin (see page 9) should be given that evening, the day before the operation. Check APTT daily, 4hours after syringe changes Fontan Circulation on Warfarin Stop warfarin 2 days prior to surgery (i.e. of the child s operation is on Tuesday, then their last dose of warfarin will be on Saturday). Note: Stop Heparin Infusion 6hrs prior to surgery Post operative Management Blalock-Taussig Shunt (BT) / Sano Shunt / Hybrid procedure stent THIS IS STANDARD TREATMENT (Any deviations from this will be decided by the surgeon and documented clearly) Start prophylactic Heparin (see page 7) 2 hours post operation, unless there are bleeding issues. Start heparin (prophylactic) at 10units/Kg/hr (No loading dose) Check APTT after 4hrs, if less than 85 continue at the same rate. In the unlikely event that the APTT is greater than 85 discuss with surgeon or intestivist. Check APTT daily, 4 hours after syringe change. Start aspirin once patient tolerating feeds. Overlap heparin and aspirin until the 2 nd dose of aspirin is given (24hrs) and then stop the heparin. 1

2 Fontan Completion THIS IS STANDARD TREATMENT (Any deviations from this will be decided by the surgeon and documented clearly) Start prophylactic Heparin (see page 7) 2 hours post operation, unless there are bleeding issues. Start heparin (prophylactic) at 10units/Kg/hr (No loading dose) Check APTT after 4hrs, if less than 85 continue at the same rate. In the unlikely event that the APTT is greater than 85 discuss with surgeon or intestivist. Check APTT daily, 4 hours after syringe change. The day after surgery stop the heparin and after 2 hours start therapeutic treatment of subcutaneous tinzaparin (therapeutic) (see page 9). Antifactor Xa monitoring is required and dosage adjustment will be required as per levels (see page 8). Start warfarin at 100microgram/Kg (max. 5mg) daily, the next day if extubated, stable and tolerating feeds. Check INR prior to starting warfarin and if greater than 1.8 discuss dosing of warfarin with the surgeons. Check INR before 2 nd dose and adjust dose accordingly. Then continue monitoring INRs daily and adjusting dose accordingly until the INR is stable. Once the INR is greater than 2, then the tinzaparin can be stopped. INR range is 2 to 3, target INR is 2.5 MVR / AVR THIS IS STANDARD TREATMENT (Any deviations from this will be decided by the surgeon and documented clearly) Start therapeutic treatment of subcutaneous tinzaparin (therapeutic) (see page 9) the morning after the operation. Antifactor Xa monitoring is required and dosage adjustment will be required as per levels (see page 9). Start warfarin at 100microgram/Kg (max. 5mg) daily, the next day if extubated, stable and tolerating feeds. Check INR prior to starting warfarin and if greater than 2 discuss dosing of warfarin with the surgeons. Check INR before 2 nd dose and adjust dose accordingly. Then continue monitoring INRs daily and adjusting dose accordingly until the INR is stable. Once the INR is greater than 2, then the tinzaparin can be stopped. MVR; INR range is 2.5 to 3.5, target INR is 3 AVR; INR range is 2 to 3, target INR is 2.5 Removal of Pacing Wires Stop heparin 6 hours prior to pacing wire removal, or stop tinzaparin 12 hours prior to pacing wire removal. Make sure the INR is equal to or less than 2.5, before the pacing wires are removed. Removal of Chest Drains If the INR is equal to or greater than 2.5, discuss with the paediatric cardiothoracic consultant. Note: The above are general guidelines only. Each patient should be treated on an individual basis in consultation with the paediatric cardiothoracic consultant. 2

3 Management of On X Plus (ONX) Aortic Valve Whilst on PICU follow the guidelines for MVR/AVR Once the patient returns to the paediatric cardiology ward the following pathway should be followed: The patient should already be on therapeutic tinzaparin and warfarin. Continue therapeutic tinzaparin (see page 9) until the INR is greater than 2. Once the INR is above 2, STOP the tinzaparin. Once the patient is tolerating enteral feeds, then start oral aspirin 5mg/Kg/dose daily (maximum of 75mg daily), this is life-long. Note; this is additional to warfarin treatment. The INR range for these patients is 2 to 3 for the first 90 days and then after this time it drops to 1.5 to 2.5. These patients will be discharged home on both aspirin and warfarin. Please make it clear on the warfarin clinic referral form that the INR range will need to be reduced after 90 days. 3

4 MEDICAL PATIENTS Anticoagulation management: Indication Blalock-Taussig Shunt / Sano Shunt/ Hybrid procedure stent Clot in the IVC/SVC/Intracardiac, extensive clots in femoral vein Femoral artery spasm following catheterisation Elective cardioversion Cardiomyopathy patient with intracardiac clots Cardiomyopathy patient with no intracardiac clots Cardiomyopathy patient with arrhythmias Kawasaki Ablation ASD device (Amplatz septal occlude, Gore device, Occlotech device) or VSD device (various) Melody valve Insertion of duct stent by cardiac catheter or right ventricular outflow tract stent Treatment Aspirin (po) 5mg/kg/dose (max. 75mg) daily (Note:post-surgery - heparin) Tinzaparin for at least 3 months starting with therapeutic heparin treatment (page 7) if necessary Start heparin at 20units/Kg/hour do not load as will have received loading dose during catheter case. Check APTT in 4hours, if greater than 85, then stop infusion and discuss with paediatric cardiologist/registrar. Discuss with cardiologist if perfusion is not improved within 4 hours, consider therapeutic treatment dose of heparin (page 7) or thrombolysis (see thrombolysis protocol and only use in conjunction with the interventional consultant responsible). Perform TOE if there is a 48 hour history or arrhythmias. If no intracardiac clots present proceed to cardioversion. If clots present anticoagulate with warfarin and cardiovert at the discretion of the cardiologist (sometimes anticoagulate for 3 months prior to procedure) INR range 2 to 3 (target INR=2.5) Start both therapeutic heparin treatment (see page 7) and warfarin at 200microgram/Kg (max. 10mg) and then monitor INR and adjust dose accordingly. Once INR is in therapeutic range, stop the heparin. Start aspirin at 5mg/kg/dose daily (max. 75mg) If warfarin required aim for INR range 2 to 3 1 month of Aspirin (po) 5mg/kg/dose (max. 75mg) daily Start Aspirin (po) 5mg/kg/dose (max. 75mg) daily for 1 week before procedure and then for 6 months after Aspirin at 5mg/kg/dose (max. 75mg) daily for at least 6 months Start heparin (prophylactic, see page 6)) at 10units/Kg/hour. Check APTT in 4hours, if greater than 85, then stop infusion and discuss with paediatric cardiologist/registrar. Overlap with Aspirin (po) 5mg/kg/dose (max. 75mg) daily for 1 day. If child is normally fully anticoagulated prior to procedure then discuss therapy with paediatric cardiologist. Occasionally full heparinisation is necessary but the interventional consultant will make a specific recommendation if this is necessary (usually when higher risk of thrombus such as competitive flows). 4

5 Children on Warfarin Indication MVR with INR less than 2 Treatment Start therapeutic treatment of subcutaneous tinzaparin (therapeutic) (see page 8). If the child is equal to or over 40Kg then antifactor Xa monitoring is not necessary, unless the child is in renal failure. If the child is less than 40Kg then antifactor Xa monitoring is required and dosage adjustment will be required as per levels (see page 8). Readjust dose of warfarin and reload. Check INR in 2 to 3 days AVR with INR less than 1.8 (Note if the patient has a ONX AVR, then the INR range is ; in these patients if the INR is constituently below 1.5, then contact the paediatric cardiologist) Fontan circulation with INR less than 1.8 Patient with arrhythmias with INR less than 2 Readjust dose of warfarin and reload. Check INR in 3 to 4 days Readjust dose of warfarin and reload if necessary. Check INR in 7 days Readjust dose of warfarin and reload if necessary. Check INR in 7 days Cardiomyopathy patient with intracardiac clots with INR less than 2 or nil by mouth (NBM) Cardiomyopathy patient with arrhythmias with INR less than 2 if on warfarin or nil by mouth (NBM) Readjust dose of warfarin and reload. Check INR in 3 to 4 days Readjust dose of warfarin and reload. Check INR in 3 to 4 days Dental procedure Discuss management with paediatric cardiologist / dentist. Usually aim for an INR less than 2.5. Titrate the warfarin dose as appropriate for warfarin indication and dental work. Pacemaker procedure Other surgery Discuss management with implanting paediatric cardiologist. If anticoagulated for a prosthetic heart valve then aim for an INR of without stopping warfarin Discuss management with paediatric cardiologist and surgeon. The surgeon needs to decide the acceptable INR required for surgery As a general rule, patients on warfarin for: 1. Fontan circulation - can stop warfarin for 3 days prior to surgery and then after surgery restart warfarin at patients maintenance dose once no signs of bleeding 2. AVR - can stop warfarin for 3 days prior to surgery and then after surgery restart warfarin, by giving a reload, followed by patients maintenance dose the next day, once no signs of bleeding 3. MVR- stop warfarin 3 days prior to surgery, measure INR daily. Start 5

6 therapeutic heparin when INR is less than 2. Give loading dose of heparin and start a continuous infusion and chase APTT according to guidelines (page 7). After surgery restart warfarin, by giving a reload, followed by patient s maintenance dose the next day, also start therapeutic subcutaneous tinzaparin (see page 8). Continue tinzaparin until the INR is 2 or above once no signs of bleeding Note; For complex congenital cardiac children with stents and shunts, these general rules may not apply and advice from the paediatric cardiologist will be required. Children on Aspirin Indication Cardiomyopathy patient with no intracardiac clots who is nil by mouth (NBM) BT shunt / conduit / Sano who is nil by mouth (NBM) Treatment Start heparin (prophylactic, see page 6)) at 10units/Kg/hour. Check APTT in 4hours, if greater than 85, then stop infusion and discuss with paediatric cardiologist/registrar Discuss management with paediatric cardiologist Definition of Intravenous Heparin for anti-coagulation Prophylactic anticoagulation of heparin: Heparin infusion to run at the rate of 10 units/kg/hour. The rate of heparin infusion does not need to be changed based on APTT level. Check clotting once daily to ensure APTT is not more than 85 secs. If APTT is greater than 85 secs, discuss with PICU Consultant, Cardiac Surgical Consultant or Paediatric Cardiologist. Therapeutic anticoagulation of heparin: Heparin infusion is used to achieve a therapeutic level for APTT (usually 60 to 85 secs). APTT should be measured 4 hours after commencing and making any changes to the infusion. Refer to therapeutic anticoagulation prescription chart for information regarding initial dose and further adjustments. 6

7 7

8 Intravenous Therapeutic Heparin Dosage Guidelines Check clotting screen prior to commencing heparin (APTT, PT and INR) Loading dose 75units/kg IV over 10 minutes Maintenance dose Children less than 1 years Children equal to or greater than 1 year 28 Units/kg/hr 20units/kg/hr Check APTT 4hrs post loading dose and after each alteration in dose APTT Value ACTION APTT less than 50 Bolus of 50units/kg and increase rate by 10% APTT Increase rate by 10% APTT Continue at same rate, check APTT, FBC daily. Check Potassium levels alternate days APTT Decrease rate by 10% APTT Stop Infusion for 30 minutes. Decrease Rate by 10% APTT greater than 120 Stop heparin for 1hour Recheck APTT, if greater than 120 reduce rate by 15% and check APTT in 4hrs To Prescribe Heparin for Therapeutic indications Use the paediatric heparin prescription chart To Reverse Effect Protamine as per guidelines on page 10 8

9 Low Molecular Weight Heparin (LMWH) Dosing: Check coagulation screen before administration TINZAPARIN Therapeutic Treatment Dose Prophylactic Dose 0 to 2 months 275units/Kg daily * See paediatric antithrombotic guideline for dose and monitoring 2 to 12 months 250units/Kg daily * 1 to 5 years 240units/Kg daily * 5 to 10 years 200units/Kg daily * 10 to 16 years 175units/Kg daily * Dose adjustment of treatment dose of LMWH Anti-Xa level (units/ml) Dose change (%) * See paediatric antithrombotic guideline for dose and monitoring (on Leeds health pathways) To Reverse Effects Protamine as per guidelines on page 10 Low molecular weight heparins in renal impairment and liver impairment. The use of unfractionated heparin may be a preferable option in renal or liver dysfunction. If low molecular weight heparin is used consider reducing dose, increasing the frequency of monitoring anti-xa levels and adjusting dose accordingly. Patients with a creatinine clearance of less than 30mL/min should receive an initial 50% dose reduction. The anti-xa level should be measured after the first dose, further monitoring and dose modifications should follow the suggested guidance. 9

10 Reversal of Heparin with Protamine Heparin Protamine Dose Time since last dose (min) < 30 1 mg per 100units heparin received mg per 100units heparin received mg per 100units heparin received > mg per 100units heparin received Maximum Dose 50mg Infusion Rate 10mg/mL, Solution should not exceed 5mg/min Treatment of Warfarin induced bleeding Major Bleeding (Limb or Life Threatening) 1. Stop Warfarin 2. Give Phytomenadione (Vitamin K1) by slow IV injection 0 to 12 years old: 50 to 100 micrograms/kg Over 12 years old: 5 to 10 mg 3. Give Prothrombin Complex Concentrate (PCC) (Factors II, VII, X) 25units/Kg or if not available Fresh Frozen Plasma (FFP) 15mL/Kg 4. Exclude local cause of bleeding INR greater than 8 no bleeding or minor bleeding 1. Stop Warfarin, restart when INR is less than 5 2. If other risk factors for bleeding exist In patients with prosthetic Mitral or Aortic Valve consider FFP at 15mL/Kg In patients with Fontan circulation, other reasons for anticoagulation consider low dose Phytomenadione (Vitamin K1) 0 to 12 years: 5 to 10 microgram/ Kg by slow intravenous injection or 50 to 100 microgram/kg orally. Repeat dose if INR remains high after 24 hours Over 12 yrs: 500 micrograms by slow intravenous injection or 5mg orally. Repeat dose if INR remains high after 24 hours INR 6 to 8, no bleeding or minor bleeding Stop Warfarin, restart when INR is less than 5 INR is greater than 6 Reduce dose, restart warfarin when INR is less than 5 Unexpected bleeding at therapeutic levels Assess for local/ systemic cause of blood loss 10

11 References These Guidelines were written according to current practice and the following references: 1. Andrew M, Marzinotto K, Massicote P et al. Heparin Therapy in Paediatric Patients: A prospective cohort study Paediatric Research 1994; 35(1): Baglin T, Barrowcliffe TW, Cohen A et al. Guidelines for use and monitoring of Heparin British Society of Haematology 2006; 133 : Dix D, Andrew M, Marizotto V et al. The use of low molecular weight heparin in paediatric patients: a prospective cohort study. Journal of Paediatrics 2000; 135: Maricotte P, Adams M, Marzinotto V et al. Low Molecular Weight Heparin in Paediatric Patients with thrombotic disease: a dose finding study. Journal of Paediatrics 1996, 128: Monagle P, Cochrane A, McCrindle B et al Thromboembolic complications after Fontan procedures- the role of prophylactic anticoagulation J Thorax Cardiovascular Surgery 1998, 115: Reller MD Congenital Heart Disease: Current Indications for Antithrombotic Therapy in Paediatric Patients Current Cardiology Reports 2001; 3: Richards M, Brooks T et al Protocol of use of anti-thrombotic treatment in children Leeds University Hospital Trust Guidelines Monagle P, Chan A et al. Antithrombotic therapy in neonates and children: Antithrombotic therapy and prevention of thrombosis, 9th ed: American college of Chest Physicians evidence- based clinical practice guidelines Chest 2012; 141(2):e737s-e801s 9. Guidelines on oral anticoagulant with warfarin, Fourth Edition, British Journal of Haematology. 2011; 154: Written by: Teresa Brooks (Advanced Clinical Pharmacist for Paediatric Cardiology) Approved by: Paediatric Cardiology Clinical Governance Written: February 2014 Review date; October 2021 Last updated: October

Paediatric Anticoagulant Guidelines. Bhavee Patel, Gareth Thomas

Paediatric Anticoagulant Guidelines. Bhavee Patel, Gareth Thomas Paediatric Anticoagulant Guidelines Author: Bhavee Patel, Gareth Thomas Specialty: Paediatrics Date Approved: 18 th July 2012 Approved by: W&CH Quality & Safety Group Date for Review: June 2015 PAEDIATRIC

More information

Pathology Service User Guide Haematology

Pathology Service User Guide Haematology Pathology Service User Guide Haematology St Richard s This section of the Pathology Service User Guide includes: Anticoagulant Therapy Information about the Anticoagulant Clinic Low Molecular Weight Heparin

More information

Antithrombotic therapy for patients with congenital heart disease. George Giannakoulas, MD, PhD AHEPA University Hospital Thessaloniki

Antithrombotic therapy for patients with congenital heart disease. George Giannakoulas, MD, PhD AHEPA University Hospital Thessaloniki Antithrombotic therapy for patients with congenital heart disease George Giannakoulas, MD, PhD AHEPA University Hospital Thessaloniki Disclosures Educational fees from Astra Zeneca, GSK Research fees from

More information

Guidelines for the management of warfarin reversal in adults

Guidelines for the management of warfarin reversal in adults SharePoint Location Clinical Policies and Guidelines SharePoint Index Directory General Policies and Guidelines Sub Area Haematology and Transfusion Key words (for search purposes) Warfarin, Bleeding Central

More information

Appendix 3 PCC Warfarin Reversal

Appendix 3 PCC Warfarin Reversal Appendix 3 PCC Warfarin Reversal Reversal of Warfarin and Analogues 1. Principle of Procedure Guidelines for the Reversal of Oral-anticoagulation in the Event of Life Threatening Haemorrhage Prothrombin

More information

2.5 Other Hematology Consult:

2.5 Other Hematology Consult: The Warfarin Order Sheet has been approved by the P & T committee to be implemented by pharmacists. These orders are not used to treat patients with serious hemorrhagic complications. WARFARIN TARGET INR

More information

Anticoagulation Therapy and Valve Surgery. Dr Pau Kiew Kong Consultant Cardiothoracic Surgeon

Anticoagulation Therapy and Valve Surgery. Dr Pau Kiew Kong Consultant Cardiothoracic Surgeon Anticoagulation Therapy and Valve Surgery Dr Pau Kiew Kong Consultant Cardiothoracic Surgeon Outline of lecture 1. Type of Valve Surgery 2. Anticoagulation requirements 3. Mechanical (Metallic) prosthetic

More information

Active date July Ratification date: Review date January 2014 Applies to: Staff managing patients on warfarin. Exclusions:

Active date July Ratification date: Review date January 2014 Applies to: Staff managing patients on warfarin. Exclusions: Guideline Title: Guidelines for the management of warfarin reversal [key words : Beriplex, Octaplex, PCC, vitamin K, anticoagulant, anticoagulation] Authors: Dr Sarah Allford, Consultant Haematologist

More information

Warfarin in Adults : Guidelines for the use of. These guidelines apply to all patients commenced or continuing on warfarin

Warfarin in Adults : Guidelines for the use of. These guidelines apply to all patients commenced or continuing on warfarin Warfarin in Adults : Guidelines for the use of Document Type: Clinical Guideline Clinical Lead: Ian Neilly Author/s: Ian Neilly/Paul Barbieri Directorate: Haematology Approved by Haematology Specialty

More information

Consensus Statement for Management of Anticoagulants and Antiplatelet drugs in Patients with Hip Fracture

Consensus Statement for Management of Anticoagulants and Antiplatelet drugs in Patients with Hip Fracture Consensus Statement for Management of Anticoagulants and Antiplatelet drugs in Patients with Hip Fracture Patients with hip fractures should be operated on within 36 hours of presentation wherever possible.

More information

GUIDELINES FOR MANAGEMENT OF BLEEDING AND EXCESSIVE ANTICOAGULATION WITH ORAL ANTICOAGULANTS

GUIDELINES FOR MANAGEMENT OF BLEEDING AND EXCESSIVE ANTICOAGULATION WITH ORAL ANTICOAGULANTS GUIDELINES FOR MANAGEMENT OF BLEEDING AND EXCESSIVE ANTICOAGULATION WITH ORAL ANTICOAGULANTS This guideline covers the management of patients being treated with Vitamin K antagonists (VKA): Warfarin Acenocoumarol

More information

Adult Reversal of Anticoagulation and Anti-platelet Agents for Life- Threatening Bleeding or Emergency Surgery Protocol

Adult Reversal of Anticoagulation and Anti-platelet Agents for Life- Threatening Bleeding or Emergency Surgery Protocol Adult Reversal of Anticoagulation and Anti-platelet Agents for Life- Threatening Bleeding or Emergency Surgery Protocol Page Platelet Inhibitors 2 Aspirin, Clopidogrel (Plavix), Prasugrel (Effient) & Ticagrelor

More information

Reference Number: Revision No: Review Cycle:

Reference Number: Revision No: Review Cycle: Policy and Procedure for the management of patients presenting with excessive anticoagulation (INR>5.0) while on warfarin at the Cork University Hospital Group. Reference Number: Revision No: Review Cycle:

More information

4.7 Algorithm for the Peri-operative Management of Anticoagulants and Antiplatelet agents in Adult patients

4.7 Algorithm for the Peri-operative Management of Anticoagulants and Antiplatelet agents in Adult patients 4.7 Algorithm for the Peri-operative Management of Anticoagulants and Antiplatelet agents in Adult patients Assess Thrombosis risk: baseline risk in an individual patient plus additional thrombotic risk

More information

DOAC and NOAC are terms for a novel class of directly acting oral anticoagulant drugs including Rivaroxaban, Apixaban, Edoxaban, and Dabigatran.

DOAC and NOAC are terms for a novel class of directly acting oral anticoagulant drugs including Rivaroxaban, Apixaban, Edoxaban, and Dabigatran. Guideline for Patients on Direct Oral Anticoagulant Therapy Requiring Urgent Surgery for Hip Fracture Trust Ref:C10/2017 1. Introduction This guideline is for the clinical management of patients on direct

More information

Oral anti-thrombotic therapy-management in patients requiring endoscopy

Oral anti-thrombotic therapy-management in patients requiring endoscopy Oral anti-thrombotic therapy-management in patients requiring endoscopy Management of anti-thrombotic therapy in patients requiring endoscopy This guideline suggests appropriate management of patients

More information

DEEP VEIN THROMBOSIS (DVT): TREATMENT

DEEP VEIN THROMBOSIS (DVT): TREATMENT DEEP VEIN THROMBOSIS (DVT): TREATMENT OBJECTIVE: To provide an evidence-based approach to treatment of patients presenting with deep vein thrombosis (DVT). BACKGROUND: An estimated 45,000 patients in Canada

More information

North East Essex Medicines Management Committee

North East Essex Medicines Management Committee Colchester Hospital University NHS Foundation Trust North East Essex Clinical Commissioning Group North East Essex Medicines Management Committee ORAL ANTICOAGULANT (Vit K antagonist only) MANAGEMENT GUIDELINES

More information

ADMINISTRATIVE CLINICAL Page 1 of 6

ADMINISTRATIVE CLINICAL Page 1 of 6 ADMINISTRATIVE CLINICAL Page 1 of 6 Anticoagulant Guidelines #2: REVERSAL OF OR MANAGEMENT OF BLEEDING WITH ANTICOAGULANTS Origination Date: Revision Date: Reviewed Date: 09/12 09/12, 01/13, 11/13, 11/15

More information

An Audit of the Post-Operative Management of Patients taking Warfarin

An Audit of the Post-Operative Management of Patients taking Warfarin An Audit of the Post-Operative Management of Patients taking Warfarin Helen Wrightson Pre-Registration Pharmacist, Salisbury District Hospital March 2014 An Audit of the Post-Operative Management of Patients

More information

Intrinsic + Common = aptt. Extrinsic + Common = PT. Common Pathway

Intrinsic + Common = aptt. Extrinsic + Common = PT. Common Pathway Anticoagulant Cases 12 11 Intrinsic + Common = aptt 9 8 10 7 4 Extrinsic + Common = PT 5 2 Common Pathway 1 Xa Inhibitors rivaroxaban (Xarelto) apixaban (Eliquis) edoxaban (Savaysa) What is true regarding

More information

ANTICOAGULATION RELATED BLEEDING - GUIDELINE SUMMARY

ANTICOAGULATION RELATED BLEEDING - GUIDELINE SUMMARY ANTICOAGULATION RELATED BLEEDING - GUIDELINE SUMMARY Click here for the full Thrombosis Prevention Investigation and Management of Anticoagulation Guideline Click on the appropriate link below: o START

More information

Reversal of Anticoagulants at UCDMC

Reversal of Anticoagulants at UCDMC Reversal of Anticoagulants at UCDMC Introduction: Bleeding complications are a common concern with the use of anticoagulant agents. In selected situations, reversing or neutralizing the effects of an anticoagulant

More information

MANAGEMENT OF OVERANTICOAGULATION AND PREOPERATIVE MANAGEMENT OF WARFARIN DOSE 1. GUIDELINES FOR THE MANAGEMENT OF AN ELEVATED INR

MANAGEMENT OF OVERANTICOAGULATION AND PREOPERATIVE MANAGEMENT OF WARFARIN DOSE 1. GUIDELINES FOR THE MANAGEMENT OF AN ELEVATED INR MANAGEMENT OF OVERANTICOAGULATION AND PREOPERATIVE MANAGEMENT OF WARFARIN DOSE 1. GUIDELINES FOR THE MANAGEMENT OF AN ELEVATED INR 1.1 Time to lower INR Prothrombinex-VF - 15 minutes Fresh Frozen Plasma

More information

MANAGEMENT OF BLEEDING AND EXCESSIVE ANTICOAGULATION IN ADULTS RECEIVING ANTI-COAGULANTS

MANAGEMENT OF BLEEDING AND EXCESSIVE ANTICOAGULATION IN ADULTS RECEIVING ANTI-COAGULANTS Hairmyres Hospital MANAGEMENT OF BLEEDING AND EXCESSIVE ANTICOAGULATION IN ADULTS RECEIVING ANTI-COAGULANTS Bleeding in patients on anticoagulants, even in the absence of over-anticoagulation, can be life-threatening

More information

Atlantic Provinces Pediatric Hematology/Oncology Network Réseau d Oncologie et Hématologie Pédiatrique des Provinces Atlantiques

Atlantic Provinces Pediatric Hematology/Oncology Network Réseau d Oncologie et Hématologie Pédiatrique des Provinces Atlantiques Atlantic Provinces Pediatric Hematology/Oncology Network Réseau d Oncologie et Hématologie Pédiatrique des Provinces Atlantiques 5850/5980 University Avenue, PO Box 9700, Halifax, NS, B3K 6R8 (902) 470-8888

More information

2. What you need to know before you are given Konakion MM. Package Leaflet: Information for the patient

2. What you need to know before you are given Konakion MM. Package Leaflet: Information for the patient Package Leaflet: Information for the patient Konakion MM Ampoules 10mg/ml solution for injection Phytomenadione (vitamin K 1 ) Roche Read all of this leaflet carefully before you start taking this medicine

More information

GUIDELINES FOR MANAGEMENT OF OVER ANTICOAGULATION WITH WARFARIN

GUIDELINES FOR MANAGEMENT OF OVER ANTICOAGULATION WITH WARFARIN GUIDELINES FOR MANAGEMENT OF OVER ANTICOAGULATION WITH WARFARIN Version Date Purpose of Issue/Description of Change Review Date 1 29/11/05 New Policy December 2007 2 Oct 07 Review Oct 09 3 March 10 Review

More information

TRANSFUSION GUIDELINES FOR CARDIOTHORACIC UNIT 2006

TRANSFUSION GUIDELINES FOR CARDIOTHORACIC UNIT 2006 TRANSFUSION GUIDELINES FOR CARDIOTHORACIC UNIT 2006 CTU blood product transfusion guidelines 2006 1 Summary of guidelines RED CELLS (10-15ml/kg) This applies to ward patients / icu patients who are stable.

More information

Bleeding Management Strategies. Aiming for the best Outcomes August 27, Amit Gupta, MD FACC FSCAI Interventional Cardiologist CANM

Bleeding Management Strategies. Aiming for the best Outcomes August 27, Amit Gupta, MD FACC FSCAI Interventional Cardiologist CANM Bleeding Management Strategies Aiming for the best Outcomes August 27, 2016 Amit Gupta, MD FACC FSCAI Interventional Cardiologist CANM Learning Objectives Review the use of anti-coagulants in patients

More information

a. A pharmacist may order a baseline SCr per protocol

a. A pharmacist may order a baseline SCr per protocol UNITYPOINT HEALTH - MARSHALLTOWN Marshalltown, Iowa PHARMACY POLICY AND PROCEDURE Subject: Anticoagulant Therapy Per Practice Protocol (Formerly Anticoagulant therapy #NPSG.03.05.01) Inpatient Warfarin

More information

ADVOCATE HEALTHCARE GUIDELINE FOR ANTITHROMBOTIC REVERSAL

ADVOCATE HEALTHCARE GUIDELINE FOR ANTITHROMBOTIC REVERSAL Minimal clinical evidence exists to support the efficacy of nonspecific procoagulant therapies that promote thrombin formation and antifibrinolytics in the setting of antithrombotic-related bleeding. Hemostatic

More information

Appendix IV - Prescribing Guidance for Apixaban

Appendix IV - Prescribing Guidance for Apixaban Appendix IV - Prescribing Guidance for Apixaban Patient Factors Dose of Apixaban If your patient has any of the following MAJOR risk factors: Hypersensitivity to the active substance or to any of the excipients

More information

ANTICOAGULANTS AND HIP FRACTURE SURGERY. Jon Antrobus Anaesthetist Borders General Hospital

ANTICOAGULANTS AND HIP FRACTURE SURGERY. Jon Antrobus Anaesthetist Borders General Hospital ANTICOAGULANTS AND HIP FRACTURE SURGERY Jon Antrobus Anaesthetist Borders General Hospital Anticoagulation is common amongst the hip fracture patient population (6-10%) Anticoagulation signifies co-morbidity

More information

Holy Crap! Why is a Cardiologist Speaking at a GI Meeting? Jonathan A. Rapp, MD, FACC, FSCAI Cardiologist, Mercy Heart Institute Cincinnati, OH

Holy Crap! Why is a Cardiologist Speaking at a GI Meeting? Jonathan A. Rapp, MD, FACC, FSCAI Cardiologist, Mercy Heart Institute Cincinnati, OH Holy Crap! Why is a Cardiologist Speaking at a GI Meeting? Jonathan A. Rapp, MD, FACC, FSCAI Cardiologist, Mercy Heart Institute Cincinnati, OH Goals and Objectives Discuss cardiac considerations for patients

More information

Thromboprophylaxis in Patients with Congenital Heart Disease. Rachel Keashen, MSN, CRNP 10/19/2018

Thromboprophylaxis in Patients with Congenital Heart Disease. Rachel Keashen, MSN, CRNP 10/19/2018 Thromboprophylaxis in Patients with Congenital Heart Disease Rachel Keashen, MSN, CRNP 10/19/2018 No disclosures/conflicts of interest COI Objectives Be able to name 2 thromboprophylaxis agents used to

More information

Title of Guideline (must include the word Guideline (not protocol, policy, procedure etc)

Title of Guideline (must include the word Guideline (not protocol, policy, procedure etc) Title of Guideline (must include the word Guideline (not protocol, policy, procedure etc) Contact Name and Job Title (author) Guideline on the management of excessive coumarin anticoagulation in adults

More information

Perioperative management of Anticoagulant and Antiplatelet medication GL067

Perioperative management of Anticoagulant and Antiplatelet medication GL067 Perioperative management of Anticoagulant and Antiplatelet medication GL067 Approval Approval Group Job Title, Chair of Committee Date Anaesthetics Clinical Governance Chair, Anaesthetics Clinical November

More information

HEPARIN-INDUCED THROMBOCYTOPENIA (HIT)

HEPARIN-INDUCED THROMBOCYTOPENIA (HIT) HEPARIN-INDUCED THROMBOCYTOPENIA (HIT) OBJECTIVE: To assist clinicians with the investigation and management of suspected and documented heparin-induced thrombocytopenia (HIT). BACKGROUND: HIT is a transient,

More information

DOCUMENT CONTROL PAGE

DOCUMENT CONTROL PAGE DOCUMENT CONTROL PAGE Title Title: UNDERGOING SPINAL DEFORMITY SURGERY Version: 2 Reference Number: Supersedes Supersedes: all other versions Description of Amendment(s): Revision of analgesia requirements

More information

How to reverse warfarin

How to reverse warfarin Page 1 of 5 How to reverse warfarin Index: Anticoagulation Original article by: Michael Tam Resources Warfarin reversal: consensus guidelines, on behalf of the Australasian Society of Thrombosis and Haemostasis

More information

Trust Guideline for the Management of: Adult patients requiring anticoagulation with Warfarin (including reversal)

Trust Guideline for the Management of: Adult patients requiring anticoagulation with Warfarin (including reversal) (including reversal) A Clinical Guideline recommended for use: In: By: For: Key words: Written by: All Clinical Areas All medical and nursing staff Adult patients requiring anticoagulation with warfarin

More information

Guidance for management of bleeding in patients taking the new oral anticoagulant drugs: rivaroxaban, dabigatran or apixaban

Guidance for management of bleeding in patients taking the new oral anticoagulant drugs: rivaroxaban, dabigatran or apixaban Guidance for management of bleeding in patients taking the new oral anticoagulant drugs: rivaroxaban, dabigatran or apixaban Purpose The aim of this guidance is to outline the management of patients presenting

More information

Using an anti-xa level nomogram to adjust intravenous unfractionated heparin infusion for arrhythmia in pregnancy

Using an anti-xa level nomogram to adjust intravenous unfractionated heparin infusion for arrhythmia in pregnancy Using an anti-xa level nomogram to adjust intravenous unfractionated heparin infusion for arrhythmia in pregnancy W. Sia, E. Toor, N. Wahab, J. Windram, R. Khurana Cardiac Problems in Pregnancy Congress

More information

Chapter 1 The Reversing Agents

Chapter 1 The Reversing Agents Available Strategies to Reverse Anticoagulant Medications Michael L. Smith, Pharm. D., BCPS, CACP East Region Pharmacy Clinical Manager Hartford HealthCare Objectives: Describe the pharmacological agents

More information

Guidelines for the Management of Anticoagulant and Anti-Platelet Agent Associated Bleeding Complications in Adults

Guidelines for the Management of Anticoagulant and Anti-Platelet Agent Associated Bleeding Complications in Adults Guidelines for the Management of Anticoagulant and Anti-Platelet Agent Associated Bleeding Complications in Adults Purpose: To be used as a common tool for all practitioners involved in the care of patients

More information

Perioperative Management of Anticoagulation

Perioperative Management of Anticoagulation Perioperative Management of Anticoagulation Presented By: Nibal R. Chamoun, PharmD, BCPS Clinical Assistant Professor, Clinical Coordinator Lebanese American University, School of Pharmacy Presented at:

More information

Slide 1: Perioperative Management of Anticoagulation

Slide 1: Perioperative Management of Anticoagulation Perioperative Management of Anticoagulation by Steven L. Cohn, MD, FACP Director, Medical Consultation Service, Kings County Hospital Center, Clinical Professor of Medicine, SUNY Downstate, Brooklyn, NY

More information

MANAGEMENT OF OVER-ANTICOAGULATION. Tammy K. Chung, Pharm.D. Critical Care & Cardiology Specialist Presbyterian Hospital Dallas

MANAGEMENT OF OVER-ANTICOAGULATION. Tammy K. Chung, Pharm.D. Critical Care & Cardiology Specialist Presbyterian Hospital Dallas MANAGEMENT OF OVER-ANTICOAGULATION Tammy K. Chung, Pharm.D. Critical Care & Cardiology Specialist Presbyterian Hospital Dallas Risk of Intracranial Hemorrhage in Outpatients (From Management of Oral Anticoagulant

More information

Use of Prothrombin Complex Concentrates (PCC) CONTENTS

Use of Prothrombin Complex Concentrates (PCC) CONTENTS CONTENTS Page 1: Exclusion Criteria and Approved Indications for Use Page 2: Dosing / Administration / Storage Page 4: Prescribing / Monitoring / Dispensing Page 5: Cautions / Warnings / Cost Analysis

More information

Bridging anticoagulation definition

Bridging anticoagulation definition Bridging anticoagulation definition Giving a short-acting anticoagulant, consisting of sc LMWH or ev UFH for 10 to 12 day period during interruption of VKA therapy when the INR is not within therapeutic

More information

Challenges in Anticoagulation and Thromboembolism

Challenges in Anticoagulation and Thromboembolism Challenges in Anticoagulation and Thromboembolism Ethan Cumbler M.D. Assistant Professor of Medicine Hospitalist Medicine Section University of Colorado Denver May 2010 No Conflicts of Interest Objectives

More information

NOTE: The first appearance of terms in bold in the body of this document (except titles) are defined terms please refer to the Definitions section.

NOTE: The first appearance of terms in bold in the body of this document (except titles) are defined terms please refer to the Definitions section. TITLE VENOUS THROMBOEMBOLISM PROPHYLAXIS SCOPE Provincial Acute and Sub-Acute Care Facilities APPROVAL AUTHORITY Alberta Health Services Executive Committee SPONSOR Vice President, Quality and Chief Medical

More information

Venothromboembolism prophylaxis: Trauma and Orthopaedics Clinical guideline, V2

Venothromboembolism prophylaxis: Trauma and Orthopaedics Clinical guideline, V2 Clinical Guideline Venothromboembolism prophylaxis: Trauma and Orthopaedics 11/11/11 TEMPORARY GUIDANCE There is no prophylactic tinzaparin available in the Trust currently. Please substitute enoxaparin

More information

Trust Guideline for the Management of: Adult patients requiring anticoagulation with Warfarin (including reversal)

Trust Guideline for the Management of: Adult patients requiring anticoagulation with Warfarin (including reversal) (including reversal) A Clinical Guideline recommended for use: For Use in: By: For: Division responsible for document: Key words: Name and job title of document author: Name and job title of document author

More information

Venous Thromboembolism Prophylaxis

Venous Thromboembolism Prophylaxis Approved by: Venous Thromboembolism Prophylaxis Vice President and Chief Medical Officer; and Vice President and Chief Operating Officer Corporate Policy & Procedures Manual Number: Date Approved January

More information

Anticoagulation Management Around Endoscopy: GI Perspective. Nathan Landesman, DO FACOI Flint Gastroenterology Associates October 11, 2017

Anticoagulation Management Around Endoscopy: GI Perspective. Nathan Landesman, DO FACOI Flint Gastroenterology Associates October 11, 2017 Anticoagulation Management Around Endoscopy: GI Perspective Nathan Landesman, DO FACOI Flint Gastroenterology Associates October 11, 2017 EDUCATIONAL OBJECTIVES Understand risks of holding anticoagulation

More information

Anticoagulation Overview Jed Delmore, MD, FACS, FACOG Professor Obstetrics and Gynecology University of Kansas School of Medicine, Wichita

Anticoagulation Overview Jed Delmore, MD, FACS, FACOG Professor Obstetrics and Gynecology University of Kansas School of Medicine, Wichita Anticoagulation Overview 2018 Jed Delmore, MD, FACS, FACOG Professor Obstetrics and Gynecology University of Kansas School of Medicine, Wichita The ideal lecture is like a miniskirt. Short enough to get

More information

Venous thrombosis is common and often occurs spontaneously, but it also frequently accompanies medical and surgical conditions, both in the community

Venous thrombosis is common and often occurs spontaneously, but it also frequently accompanies medical and surgical conditions, both in the community Venous Thrombosis Venous Thrombosis It occurs mainly in the deep veins of the leg (deep vein thrombosis, DVT), from which parts of the clot frequently embolize to the lungs (pulmonary embolism, PE). Fewer

More information

Risk Factor Evaluation for Thrombosis and Bleeding in Pediatric Patients with Heart Disease

Risk Factor Evaluation for Thrombosis and Bleeding in Pediatric Patients with Heart Disease Risk Factor Evaluation for Thrombosis and Bleeding in Pediatric Patients with Heart Disease Kristen Nelson, MD Johns Hopkins University Director, Pediatric Cardiac Critical Care Why Does it Matter? Pediatric

More information

Joost van Veen Consultant Haematologist

Joost van Veen Consultant Haematologist Joost van Veen Consultant Haematologist Bridging anticoagulation - conclusion Aim Questions What is the evidence? Does oral anticoagulation need to be stopped and if so when? When and at what dose is alternative

More information

ANTITHROMBOTIC THERAPY 2010 Antitrombotik tedavi alan hastalarda operasyon hazırlığı

ANTITHROMBOTIC THERAPY 2010 Antitrombotik tedavi alan hastalarda operasyon hazırlığı ANTITHROMBOTIC THERAPY 2010 Antitrombotik tedavi alan hastalarda operasyon hazırlığı Dr. Sabri DEMİRCAN Ondokuz Mayıs Üniversitesi Tıp Fakültesi Kardiyoloji ABD, Samsun Copyright 2001 Harcourt Canada Ltd.

More information

Prostate Biopsy Alerts

Prostate Biopsy Alerts Prostate Biopsy Alerts Saskatchewan Prostate Assessment Pathway Guidelines for the Primary Care Provider for Patient Preparation and the Management of Medications and Complications September 2016 Table

More information

Doncaster & Bassetlaw Medicines Formulary

Doncaster & Bassetlaw Medicines Formulary Doncaster & Bassetlaw Medicines Formulary Section 2.9: Antiplatelet Drugs Aspirin 75mg Dispersible Tablets Aspirin 300mg Dispersible Tablets Aspirin 300mg Suppositories Clopidogrel 75mg Tablets Dipyridamole

More information

2017 Bryan Health Primary Care Conference. Dale Hansen MD Bryan Heart 5/20/17

2017 Bryan Health Primary Care Conference. Dale Hansen MD Bryan Heart 5/20/17 2017 Bryan Health Primary Care Conference Dale Hansen MD Bryan Heart 5/20/17 I have no financial disclosures or conflicts of interest Bridging Anticoagulation Primum Non Nocere 67 y.o. male with mechanical

More information

Package leaflet: Information for the patient. Konakion MM Ampoules 10mg/ml solution for injection and oral solution Phytomenadione (vitamin K 1 )

Package leaflet: Information for the patient. Konakion MM Ampoules 10mg/ml solution for injection and oral solution Phytomenadione (vitamin K 1 ) Package leaflet: Information for the patient Konakion MM Ampoules 10mg/ml solution for injection and oral solution Phytomenadione (vitamin K 1 ) Roche Read all of this leaflet carefully before you start

More information

Treatment Options and How They Work

Treatment Options and How They Work Treatment Options and How They Work Robin Offord Director of Clinical Pharmacy UCL Hospitals NHS Foundation Trust robin.offord@uclh.nhs.uk Introducing the term anticoagulant... What they do Inhibit the

More information

Shared Care Protocol for the Prescription and Supply of Low Molecular Weight Heparins

Shared Care Protocol for the Prescription and Supply of Low Molecular Weight Heparins Tameside Hospital NHS Foundation Trust and NHS Tameside and Glossop Shared Care Protocol for the Prescription and Supply of Low Molecular Weight Heparins Version 5.2 Version: 5.2 Authorised by: Joint Medicines

More information

Blood Thinner Agent. Done by: Meznah Al-mutairi Pharm.D Candidate PNU Collage of Pharmacy

Blood Thinner Agent. Done by: Meznah Al-mutairi Pharm.D Candidate PNU Collage of Pharmacy Blood Thinner Agent Done by: Meznah Al-mutairi Pharm.D Candidate PNU Collage of Pharmacy Outline: Blood thinner agent definition. anticoagulants drugs. Thrombolytics. Blood thinner agent Therapeutic interference

More information

Challenging Anticoagulation Case Studies. Earl J. Hope, M.D. Tower Health Cardiology

Challenging Anticoagulation Case Studies. Earl J. Hope, M.D. Tower Health Cardiology Challenging Anticoagulation Case Studies Earl J. Hope, M.D. Tower Health Cardiology Financial Disclosures Nothing to disclose Objectives: 1. Understand indications for heparin bridging. 2. Recognize the

More information

Prothrombin Complex Concentrate- Octaplex. Octaplex

Prothrombin Complex Concentrate- Octaplex. Octaplex Prothrombin Complex Concentrate- Concentrated Factors Prothrombin Complex Concentrate (PCC) 3- factor (factor II, IX, X) 4-factor (factors II, VII, IX, X) Activated 4-factor (factors II, VIIa, IX, X) Coagulation

More information

These are guidelines only and can be deviated from if it is thought to be in the patient s best interest.

These are guidelines only and can be deviated from if it is thought to be in the patient s best interest. Clinical Guideline Venothromboembolism prophylaxis: Trauma and Orthopaedics Venous thromboembolism (VTE) is a recognised complication associated with inactivity and surgical procedures. Therefore, all

More information

Coagulation, Haemostasis and interpretation of Coagulation tests

Coagulation, Haemostasis and interpretation of Coagulation tests Coagulation, Haemostasis and interpretation of Coagulation tests Learning Outcomes Indicate the normal ranges for routine clotting screen and explain what each measurement means Recognise how to detect

More information

Emergent Anticoagulation Reversal

Emergent Anticoagulation Reversal U N C M E D I C A L C E N T E R G U I D E L I N E Emergent Anticoagulation Reversal I. PURPOSE: The purpose of these instructions is to provide guidelines for the reversal of or management of bleeding

More information

Edoxaban for the treatment and prevention of venous thromboembolism (DVT or PE) or stroke prevention in non-valvular AF

Edoxaban for the treatment and prevention of venous thromboembolism (DVT or PE) or stroke prevention in non-valvular AF Edoxaban for the treatment and prevention of venous thromboembolism (DVT or PE) or stroke prevention in non-valvular AF Traffic light classification- Amber 2 specialist initiation / recommendation Information

More information

Clinical Practice Committee Anticoagulation Bridging Document

Clinical Practice Committee Anticoagulation Bridging Document Original: 10/23/06 Last Updated: 10/30/07 Clinical Practice Committee Do patients on long term oral anticoagulant therapy who require short term interruption of warfarin for an elective invasive procedure

More information

Antithrombotic Therapy in Neonates and Children

Antithrombotic Therapy in Neonates and Children CHEST Supplement ANTITHROMBOTIC THERAPY AND PREVENTION OF THROMBOSIS, 9TH ED: ACCP GUIDELINES Antithrombotic Therapy in Neonates and Children Antithrombotic Therapy and Prevention of Thrombosis, 9th ed:

More information

John Davidson Consultant in Intensive Care Medicine Freeman Hospital, Newcastle upon Tyne

John Davidson Consultant in Intensive Care Medicine Freeman Hospital, Newcastle upon Tyne John Davidson Consultant in Intensive Care Medicine Freeman Hospital, Newcastle upon Tyne Overview of coagulation Testing coagulation Coagulopathy in ICU Incidence Causes Evaluation Management Coagulation

More information

Clinicians and Facilities: RESOURCES WHEN CARING FOR WOMEN WITH ADULT CONGENITAL HEART DISEASE OR OTHER FORMS OF CARDIOVASCULAR DISEASE!!

Clinicians and Facilities: RESOURCES WHEN CARING FOR WOMEN WITH ADULT CONGENITAL HEART DISEASE OR OTHER FORMS OF CARDIOVASCULAR DISEASE!! Clinicians and Facilities: RESOURCES WHEN CARING FOR WOMEN WITH ADULT CONGENITAL HEART DISEASE OR OTHER FORMS OF CARDIOVASCULAR DISEASE!! Abha'Khandelwal,'MD,'MS' 'Stanford'University'School'of'Medicine'

More information

What s new with DOACs? Defining place in therapy for edoxaban &

What s new with DOACs? Defining place in therapy for edoxaban & What s new with DOACs? Defining place in therapy for edoxaban & Use of DOACs in cardioversion Caitlin M. Gibson, PharmD, BCPS Assistant Professor, Department of Pharmacotherapy University of North Texas

More information

Incorporated Dosing Guidelines: Intravenous Heparin Therapy Initial Dose

Incorporated Dosing Guidelines: Intravenous Heparin Therapy Initial Dose Intravenous Heparin Therapy Initial Dose (Max Dose) IV Infusion Rate IV Infusion Rate (Max Dose) Lab Tests High Dose 80 units/kg 8,000 units 18 units/kg/hr 1,800 units/hr Intermediate Dose 5,000 units

More information

LAPAROSCOPIC PYELOPLASTY INFORMATION LEAFLET

LAPAROSCOPIC PYELOPLASTY INFORMATION LEAFLET LAPAROSCOPIC PYELOPLASTY INFORMATION LEAFLET Laparoscopic Pyeloplasty Page 1 of 8 LAPAROSCOPIC PYELOPLASTY This leaflet has been written to answers questions that you may have about your operation. If

More information

WARFARIN: PERI OPERATIVE MANAGEMENT

WARFARIN: PERI OPERATIVE MANAGEMENT WARFARIN: PERI OPERATIVE MANAGEMENT OBJECTIVE: To provide an approach to the perioperative management of warfarin treated patients who require an elective or urgent surgery/procedure. To provide an approach

More information

Focused. se with 2008 F. lar Heart Diseas. date. ents With Valvul. Upd. gement of Patie. lines for Manag. HA 2006 Guidel ACC/AH. Fig.

Focused. se with 2008 F. lar Heart Diseas. date. ents With Valvul. Upd. gement of Patie. lines for Manag. HA 2006 Guidel ACC/AH. Fig. ACC/AH HA 2006 Guidel nic severe AI (Fig. 4). ned by age, ay also be helpful nd echo. For AI, ollow up may be or MRI rather than mension; SD, end lines for Manag gement of Patie Upd ents With Valvul date

More information

Clinical Guideline for Anticoagulation in VTE

Clinical Guideline for Anticoagulation in VTE Clinical Guideline for Anticoagulation in VTE These clinical guidelines are intended to provide evidence-based recommendations regarding the anticoagulation in patients with DVT and PE. Please note that

More information

3/19/2012. What is the indication for anticoagulation? Has the patient previously been on warfarin? If so, what % of the time was the INR therapeutic?

3/19/2012. What is the indication for anticoagulation? Has the patient previously been on warfarin? If so, what % of the time was the INR therapeutic? Abigail E. Miller, PharmD, BCPS Clinical Specialist, Cardiology University of North Carolina Hospitals I have no personal financial relationships with the manufacturers of the products to disclose. Boehringer

More information

Transcatheter Aortic Valve Implantation (TAVI) PROOF. Patient Information leaflet. Lancashire Cardiac Centre

Transcatheter Aortic Valve Implantation (TAVI) PROOF. Patient Information leaflet. Lancashire Cardiac Centre Transcatheter Aortic Valve Implantation (TAVI) Patient Information leaflet Lancashire Cardiac Centre Welcome to the Lancashire Cardiac Centre During your admission you will be admitted to Ward 37. Ward

More information

Anticoagulation in Special populations. Ng Heng Joo Department of Haematology Singapore General Hospital

Anticoagulation in Special populations. Ng Heng Joo Department of Haematology Singapore General Hospital Anticoagulation in Special populations Ng Heng Joo Department of Haematology Singapore General Hospital roymatheson.com Objectives Safer anticoagulation for The elderly Chronic kidney disease Obese patients

More information

Primary Care practice clinics within the Edmonton Southside Primary Care Network.

Primary Care practice clinics within the Edmonton Southside Primary Care Network. INR Monitoring and Warfarin Dose Adjustment Last Review: November 2016 Intervention(s) and/or Procedure: Registered Nurses (RNs) adjust warfarin dosage according to individual patient International Normalized

More information

Dental Management Considerations for Patients on Antithrombotic Therapy

Dental Management Considerations for Patients on Antithrombotic Therapy Dental Management Considerations for Patients on Antithrombotic Therapy Warfarin and Antiplatelet Joel J. Napeñas DDS FDSRCS(Ed) Program Director General Practice Residency Program Department of Oral Medicine

More information

Patients on anticoagulant or antiplatelet therapy undergoing elective endoscopic procedures

Patients on anticoagulant or antiplatelet therapy undergoing elective endoscopic procedures This is an official Northern Trust policy and should not be edited in any way Patients on anticoagulant or antiplatelet therapy undergoing elective endoscopic procedures Reference Number: NHSCT/11/454

More information

WARFARIN: PERI-OPERATIVE MANAGEMENT

WARFARIN: PERI-OPERATIVE MANAGEMENT WARFARIN: PERI-OPERATIVE MANAGEMENT OBJECTIVE: To provide an approach to the perioperative management of warfarin-treated patients who require an elective or urgent surgery/procedure. To provide an approach

More information

New Oral Anticoagulants in treatment of VTE, PE DR.AMR HANAFY (LECTURER OF CARDIOLOGY ) ASWAN UNIVERSITY

New Oral Anticoagulants in treatment of VTE, PE DR.AMR HANAFY (LECTURER OF CARDIOLOGY ) ASWAN UNIVERSITY New Oral Anticoagulants in treatment of VTE, PE DR.AMR HANAFY (LECTURER OF CARDIOLOGY ) ASWAN UNIVERSITY Fact VTE is deadly! It nibbles after it bites! The 30-day mortality rates for first-time DVT or

More information

Developed for Scotland by the National Plasma Product Expert Advisory Group (NPPEAG)

Developed for Scotland by the National Plasma Product Expert Advisory Group (NPPEAG) Approved by NPPEAG 18 December 2018 Reviewed 18 December 2018 To be reviewed 18 December 2020 Developed for Scotland by the National Plasma Product Expert Advisory Group (NPPEAG) Protocol for the Reversal

More information

THROMBOPROPHYLAXIS: NON-ORTHOPEDIC SURGERY

THROMBOPROPHYLAXIS: NON-ORTHOPEDIC SURGERY THROMBOPROPHYLAXIS: NON-ORTHOPEDIC SURGERY OBJECTIVE: To outline a practical approach for the prevention of venous thromboembolism (VTE) in patients undergoing non-orthopedic surgery. BACKGROUND: VTE is

More information

HEART OF THE MATTER: cardiac issues in safe endoscopy & sedation

HEART OF THE MATTER: cardiac issues in safe endoscopy & sedation HEART OF THE MATTER: cardiac issues in safe endoscopy & sedation YUVAL KONSTANTINO M.D. CARDIOLOGY DEPARTMENT, ELECTROPHYSIOLOGY UNIT, SOROKA MEDICAL CENTER, BEN-GURION UNIVERSITY OUTLINE 1 2 3 Anticoagulation

More information

PULMONARY EMBOLISM (PE): DIAGNOSIS AND TREATMENT

PULMONARY EMBOLISM (PE): DIAGNOSIS AND TREATMENT PULMONARY EMBOLISM (PE): DIAGNOSIS AND TREATMENT OBJECTIVE: To provide a diagnostic algorithm and treatment options for patients with acute pulmonary embolism (PE). BACKGROUND: Venous thromboembolism (VTE)

More information

NOACS/DOACS*: COAGULATION TESTS

NOACS/DOACS*: COAGULATION TESTS NOACS/DOACS*: COAGULATION TESTS OBJECTIVES: To describe the effect of the newer direct oral anticoagulants (DOACs) on laboratory coagulation tests which are widely available: prothrombin time (PT), international

More information

ATLANTIC HEALTH GUIDELINES FOR ANTICOAGULANT, ANTIPLATELET, AND THROMBOLYTIC REVERSAL IN ADULT PATIENTS

ATLANTIC HEALTH GUIDELINES FOR ANTICOAGULANT, ANTIPLATELET, AND THROMBOLYTIC REVERSAL IN ADULT PATIENTS ATLANTIC HEALTH GUIDELINES FOR ANTICOAGULANT, ANTIPLATELET, THROMBOLYTIC REVERSAL IN ADULT PATIENTS Several of the below interventions are based on low-level evidence and are intended as suggestions only.

More information

(e.g. inclusion and exclusion criteria, diagnosis) anticoagulation Future management of HIT patients post acute phase

(e.g. inclusion and exclusion criteria, diagnosis) anticoagulation Future management of HIT patients post acute phase Title of Guideline (must include the word Guideline (not protocol, policy, procedure etc) Contact Name and Job Title (author) Guideline for the treatment of heparin induced thrombocytopenia (HIT) in adults

More information